D28

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024

Retrieved on: 
Mardi, mai 7, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, EAP, Cancer, MET, Congress, Safety, Haematopoietic system, Survival, Institut Gustave Roussy, Maat, Partnership, Trial of the century, Artificial intelligence, AP-HP, DSMB, ICI, IGR, PICASSO, Rated R, Patient, ARES, Doctor of Pharmacy, D28, INRAE, Lung, EBMT, ALS, AACR, NSCLC, Lung cancer, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.
  • Hervé Affagard, CEO and co-founder of MaaT Pharma said: “We're confidently advancing towards Phase 3 results for MaaT013, meeting milestones and delivering value for shareholders.
  • This study was not requested by regulatory authorities and does not impact cash projections as funding has already been secured.
  • The related costs for MaaT Pharma are limited to clinical product supply in line with previous cash projections.

MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

Retrieved on: 
Lundi, avril 15, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, FDA, EAP, Cancer, MET, Hospital, Hematology, Food, Sorbonne University, Survival, Orphan, OS, DSMB, Disease, Rated R, Patient, ARES, D28, EMA, Symantec Endpoint Protection, Hematopoietic stem cell transplantation, EBMT, Toxicity, European Medicines Agency, Data monitoring committee, Pharmaceutical industry

Prof. Malard commented: “MaaT013 shows remarkable efficacy at 18 months, yielding more complete responses in aGvHD patients who have shown resistance to current treatments, as compared to other available therapies.

Key Points: 
  • Prof. Malard commented: “MaaT013 shows remarkable efficacy at 18 months, yielding more complete responses in aGvHD patients who have shown resistance to current treatments, as compared to other available therapies.
  • Notably, these results are achieved with just 3 doses in less than 2 weeks of treatment initiation.
  • The data presented highlights the strong safety profile of MaaT013 (full details here ) and translates into increased OS.
  • MaaT Pharma also presented its ongoing Phase 2b trial design for MaaT033 developed as an adjunctive therapy to enhance OS in allogeneic hematopoietic stem cell transplantation.

MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

Retrieved on: 
Mardi, mars 12, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Rated R, Toxicity, Survival, ASH, Hematology, Risk, Patient, Hospital, ARES, EAP, Policy, Cancer, Quality of life, MET, DSMB, D28, Pharmaceutical industry

Details from the presentation will be disclosed in a press release on April 17th, 2024, in compliance with the conference embargo policy.

Key Points: 
  • Details from the presentation will be disclosed in a press release on April 17th, 2024, in compliance with the conference embargo policy.
  • Aligned with its mission to enhance the survival of cancer patients, MaaT Pharma has been actively involved in the EAP in Europe since 2019.
  • The Company has consistently presented real-world data from its EAP at major hematology conferences over the past four years.
  • To date, over 220 patients have been treated with MaaT013 in Europe in clinical trials and the EAP.

Sensorion Update on SENS-401

Retrieved on: 
Jeudi, mars 17, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Hearing, Breast implant, Mutation, Ear, US, Review, Patient, Degenerative disease, Usher syndrome, FDA, D28, PTA, Diagnosis, US Foods, Investigational New Drug, IND, Biomarker, Food, Deafness, Company, Communication, Genetics, ITT, CEO, Population, Cochlear Limited, Hearing loss, CIO, Pasteur Institute, Intention, Dentistry, Pharmaceutical industry, Medicine, Medical device, Sensorion, SENS-401, SENSORION, SENS-401

Sensorion plans to provide an update on its clinical development plans for these indications in due course.

Key Points: 
  • Sensorion plans to provide an update on its clinical development plans for these indications in due course.
  • In addition, Sensorion and its partner Cochlear Limited (Cochlear) will advance with a trial of SENS-401 for hearing preservation in patients following cochlear implantation.
  • Sensorion and Cochlear have submitted the proposed trial design for SENS-401 in patients scheduled for cochlear implantation to regulatory authorities in Australia and France.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion.